Amarin flags new REDUCE-IT analyses for presentation at ESC Congress 2026
AMRN•Mechanistic work on EPA and vascular responses
Mechanistic work suggests EPA could support favorable vascular cell responses linked to lipoprotein(a), reinforcing the drug’s broader cardiovascular rationale.
Readouts are scheduled across late August sessions, keeping investor attention on incremental evidence rather than a new pivotal efficacy result.
REDUCE-IT analyses scheduled for ESC Congress 2026
Amarin flagged new REDUCE-IT analyses for presentation at the ESC Congress 2026 in Munich on Aug. 28-31.
The data focus on adherence, long-term outcomes, and biomarkers tied to cardiovascular risk, aiming to clarify how icosapent ethyl may drive benefit.
